$839.87
2.44% day before yesterday
NYSE, Oct 03, 10:11 pm CET
ISIN
US5324571083
Symbol
LLY

Eli Lilly and Company Stock News

Positive
Seeking Alpha
2 days ago
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, especially from LLY and NVO, provide powerful tailwinds for the sector. Advances in oncology, hematology, and new cardiology drugs like Lp(a) inhibitors create multi-billion dollar opportunities for...
Neutral
The Motley Fool
2 days ago
Shares in Eli Lilly (LLY 2.73%) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical company three years of grace from tariffs imposed on drugs it manufactures abroad and imports to the U.S..
Positive
Seeking Alpha
2 days ago
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future return estimates of at least 10%, with 15 appearing potentially undervalued by my Free Cash Flow model. Top-ranked stocks include MKTX, RMD, MPWR, RACE, and MSCI, each offering strong projected ret...
Neutral
Business Wire
2 days ago
BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.
Positive
Forbes
2 days ago
The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most major pharma stocks have rallied, Eli Lilly stock (NYSE: LLY) warrants particular attention.
Neutral
Seeking Alpha
2 days ago
Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven...
Positive
Seeking Alpha
3 days ago
Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV's largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle. Orforglipron, first true oral GLP-1, solves compliance issues and expands TAM. LLY's $1B pre-launch inventory and $15B+ capex signal FDA approval certainty and industrialized pill-based obesity treat...
Positive
Forbes
3 days ago
AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs. Since the market sees this event as broadly positive for pharmaceutical companies, ABBV's stock has risen significantly.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today